Xu W, Liu P, Mu YP. Research progress on signaling pathways in cirrhotic portal hypertension. World J Clin Cases 2018; 6(10): 335-343 [PMID: 30283796 DOI: 10.12998/wjcc.v6.i10.335]
Corresponding Author of This Article
Yong-Ping Mu, PhD, Attending Doctor, Department of Gastroenterology and Hepatology, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (TCM), 528 Zhangheng Road, Pudong District, Shanghai 201203, China. ypmu8888@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 26, 2018; 6(10): 335-343 Published online Sep 26, 2018. doi: 10.12998/wjcc.v6.i10.335
Research progress on signaling pathways in cirrhotic portal hypertension
Wen Xu, Ping Liu, Yong-Ping Mu
Wen Xu, Ping Liu, Yong-Ping Mu, Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (TCM), Shanghai 201203, China
Wen Xu, Ping Liu, Yong-Ping Mu, Key Laboratory of Liver and Kidney Disease of the Ministry of Education, Shanghai University of TCM, Shanghai 201203, China
Wen Xu, Ping Liu, Yong-Ping Mu, Clinical key laboratory of TCM of Shanghai, Shanghai 201203, China
Author contributions: Xu W wrote the paper and performed the research; Liu P and Mu YP designed the study.
Supported bythe National Natural Science Foundation of China, No. 81573948.
Conflict-of-interest statement: We declare that we have no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yong-Ping Mu, PhD, Attending Doctor, Department of Gastroenterology and Hepatology, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (TCM), 528 Zhangheng Road, Pudong District, Shanghai 201203, China. ypmu8888@126.com
Telephone: +86-21-20256526 Fax: +86-21-20256521
Received: May 28, 2018 Peer-review started: May 28, 2018 First decision: July 3, 2018 Revised: July 23, 2018 Accepted: August 3, 2018 Article in press: August 4, 2018 Published online: September 26, 2018 Processing time: 121 Days and 5.1 Hours
Abstract
Portal hypertension (PHT) is an important consequence of liver cirrhosis, which can lead to complications that adversely affect a patient’s quality of life and survival, such as upper gastrointestinal bleeding, ascites, and portosystemic encephalopathy. In recent years, advances in molecular biology have led to major discoveries in the pathological processes of PHT, including the signaling pathways that may be involved: PI3K-AKT-mTOR, RhoA/Rho-kinase, JAK2/STAT3, and farnesoid X receptor. However, the pathogenesis of PHT is complex and there are numerous pathways involved. Therefore, the targeting of signaling pathways for medical management is lagging. This article summarizes the progress that has been made in understanding the signaling pathways in PHT, and provides ideas for treatment of the disorder.
Core tip: Portal hypertension (PHT) is a syndrome of portal venous system hemodynamics in liver cirrhosis. Current therapeutic options are often insufficient to prevent progression of the disease. We therefore may find more effective clinical treatments by understanding the signal pathways involved in the disease. This paper is an up-to-date and thorough review of the signaling pathways that may be involved in the pathogenesis of PHT in liver cirrhosis.
